SCHEMBL7536798

SCHEMBL7536798

CCC(C)Oc1ccccc1CN.O=C(O)c1ccc2cccnc2n1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
KDM4E B2RXH2 1/20 0.53
LMNA P02545 1/20 0.53
MCHR1 Q99705 1/20 0.39
MAPK8 P45983 1/20 0.37
DPP4 P27487 1/20 0.35
DPP9 Q86TI2 1/20 0.35
HTT P42858 1/20 0.34
MGAM O43451 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33
CYSLTR1 Q9Y271 1/20 0.33
USP9X Q93008 1/20 0.33
ADORA3 P0DMS8 3/20 0.32
SUCNR1 Q9BXA5 1/20 0.32
POLB P06746 1/20 0.32
SLC6A2 P23975 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7015564 0.85 MEN1 (0.60) MEN1KMT2AKDM4ELMNAMGAM
SCHEMBL7010073 0.82 MEN1 (0.52) MEN1KMT2AKDM4ELMNAMAPK8
SCHEMBL27359670 0.80 LMNA (0.41) MEN1KMT2AKDM4ELMNAMCHR1
SCHEMBL7013166 0.74 MCHR1 (0.46) MEN1KMT2ALMNAMCHR1DPP4
Methoxymethane SCHEMBL27938732 0.73 KDM4E (0.87) MEN1KMT2AKDM4ELMNAHTT
SCHEMBL30505600 0.73 KDM4E (1.00) MEN1KMT2AKDM4ELMNADPP4
SCHEMBL125654 0.73 KDM4E (1.00) MEN1KMT2AKDM4ELMNADPP4
SCHEMBL30381290 0.73 KDM4E (1.00) MEN1KMT2AKDM4ELMNADPP4
SCHEMBL7015349 0.72 MEN1 (0.55) MEN1KMT2AKDM4ELMNAMAPK8
Fluoride SCHEMBL28821496 0.71 KDM4E (0.96) MEN1KMT2AKDM4ELMNADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020099072-A1 [1,8] naphthyridine derivatives having antiviral activity BIOCHEM PHARMA INC. 2002-07-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099072-A1 [1,8] naphthyridine derivatives having antiviral activity HAVCR2, MAVS, NTPCR MEN1 4721/4885KMT2A 4352/4885KDM4E 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.